临床医学专业-AMD诊断和治疗新进展.pptVIP

Manufacturing standards for ophthalmic injections are much more stringent with regards to sterility and particulate matter. Bevacizumab was developed for applications in oncology and has not been registered for any application in ophthalmology in any country. Ranibizumab was developed specifically for ocular use. Therefore, ranibizumab (but not bevacizumab) is manufactured according to US Pharmacopoeia specifications for injections into the eye. In intravenous medications (such as bevacizumab) more particulate matter is tolerated, but this may cause irritation and inflammation if injected in